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Background: Acute presentation of herpes zoster (HZ) and the subsequent development of post-herpetic neuralgia
(PHN) can have a significant impact on patients’ lives. To date, evidence regarding the human and economic
burden of HZ and PHN in the UK is limited. To address this knowledge gap a national, multicentre, large-scale
real-world study was conducted to inform the scientific community and healthcare decision-makers. This paper
outlines difficulties encountered and challenges to conducting real-world studies in the UK, methods used
to overcome these hurdles and strategies that can be employed to promote and facilitate the conduct of
future studies.
Findings: The Zoster Quality of Life (ZQOL) study is the first UK-wide and largest observational study investigating
patient burden associated with HZ and PHN. A total of 383 patients (229 HZ; 154 PHN) over the age of 50 years were
recruited from 42 primary and secondary/tertiary care centres. Patient-reported outcome (PRO) assessments of pain,
quality of life and treatment satisfaction were completed by all participants and supplemented by clinical information
from participating physicians.
Key challenges encountered during the conduct of this study can be broadly categorised as follows: 1) identification of
centres willing/able to participate in the study: lack of resources and limited research experience were major
barriers to recruitment of centres for participation in the study; 2) obtaining local research & development (R&D)
approval: lack of clearly defined processes and requirements specific to real-world studies and limited degree of
standardisation between R&D departments in approval procedures led to significant variability in submission
requirements and lead times for obtaining approval; 3) recruitment of study participants: rates of recruitment
were slower than anticipated, meaning it was necessary to extend the study recruitment period and increase the
number of participating centres.
Discussion: Initiatives designed to promote and facilitate the conduct of research in the UK are important for
real-world studies. The ZQOL study shows that opportunities exist for real-word research. However, streamlining
the R&D approval process where possible and further incentivising the participation of primary care centres in such
studies would help to further facilitate the generation of real-world evidence to inform healthcare decisions.
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Herpes Zoster (HZ), often referred to as ‘shingles’, is a
viral condition resulting from reactivation of latent
varicella-zoster virus (VZV) which is responsible for
childhood ‘chickenpox’. The condition is characterised
by a painful skin rash and blisters on one side of the
body. It is estimated to affect one in four persons during
their lifetime, with an estimated 200,000 episodes in the
UK annually [1-3]. Whilst anyone previously infected
with the VZV (i.e. has had “chickenpox”) is at risk of
developing shingles, incidence increases with age and is
most prevalent among those patients aged 50 years and
over [4]. The dermatological rash and pain associated with
HZ typically resolve within one month of presentation,
however approximately 20% of sufferers will continue
to experience pain in the area of the rash, following
resolution [4]. Although variable definitions exist, instances
where pain persists for > 90 days after the onset of the rash
are typically referred to as post-herpetic neuralgia (PHN)
[5]. The incidence of PHN increases markedly with age
and is also associated with the severity of pain experienced
during the preceding HZ episode as well as the extent of
the rash [6].
Previous cross-sectional, epidemiological studies have
demonstrated that the pain associated with HZ and PHN
can have a significant impact on patients’ Health-related
Quality of Life (HRQoL) [6-13]. In particular, patients
who develop PHN may experience pain and associated
reductions in HRQoL long after the initial acute presenta-
tion of the HZ rash, with some patients reporting persistent
pain for more than ten years [10]. In addition to the burden
encountered by the individual, HZ and PHN are also
associated with considerable societal burden. Care provision
for HZ and PHN patients, in terms of visits to primary
care (general practitioner centres) and outpatient secondary/
tertiary care centres (specialist pain clinics and ophthalmol-
ogists), inpatient visits (hospitalisations) and prescription
costs, for example, is at considerable cost to healthcare
systems [14-19]. In addition, HZ and PHN are also asso-
ciated with significant indirect costs, primarily in terms
of loss of productivity for patients and caregivers [9,15].
This is particularly relevant for those patients with Herpes
Zoster Ophthalmicus (HZO) and/or with long-standing or
severe PHN.
Key to worldwide health authority initiatives is the
prioritisation of preventative measures, so as to reduce
the burden on healthcare conditions on individuals,
healthcare systems and society as a whole. This is evident
in the UK by the recent introduction of the Quality,
Innovation, Productivity and Prevention (QIPP) initiative,
which outlines the UK Government’s commitment to
supporting research to provide new knowledge needed
to improve health outcomes and reduce inequalities by
facilitating advances in disease prevention, diagnosisand treatment [http://www.improvement.nhs.uk/Default.
aspx?alias=www.improvement.nhs.uk/qipp; Accessed 13th
August 2012]. Typically, management of HZ/PHN has
centred upon the use of antivirals (usually prescribed
within 72 hours of the onset of the rash) to treat the
initial infection and initial regulation of pain using pre-
scribed and/or over-the-counter pain medication and pre-
scribed antidepressants and anticonvulsants thereafter to
modulate persisting pain. Recent years, however, have seen
documented evidence of the efficacy of VZV vaccines in
the prevention of HZ and PHN episodes and attenuation
of the severity of HZ and PHN episodes and associated
impact [20].
The value of real-world data summarising patients’
experiences of living with a health condition in informing
decisions regarding access to new medicines in national
markets is becoming increasingly recognised. Indeed,
as stipulated in the Government’s Health and Social Care
Bill (HSCB), the proposed commissioning outcomes frame-
work, which is a fundamental foundation of the proposed
NHS reforms in England, will place a strong emphasis
on promoting decision-making that is driven by the patient
experience – as likely measured by patient reported
outcome (PRO) measures [21].
To date, there has only been limited real-world evaluation
of the burden of HZ and PHN specific to UK patients, and
what research has been conducted is limited by relatively
small sample sizes and a lack of geographic representation
[9]. However, UK-specific data is valuable to generate best
available evidence for appraising the cost-effectiveness of
strategies for the prevention and/or management of HZ
and PHN (including VZV vaccines). So far, such appraisals
have incorporated data derived from HZ and PHN patients
in the US and Europe [14,22]. There is a need, therefore,
for the generation of more information to accurately
ascertain disease burden in UK patients, a view expressed
by the UK Joint Committee on Vaccination and Immunisa-
tion (JCVI) [23,24]. To address this need the Zoster Quality
of Life (ZQOL) study, the first UK-wide and largest
evaluation of the experiences of HZ and PHN patients
conducted to date, was initiated in August 2009.
The current paper outlines experiences and insights
from the conduct of the ZQOL study with a reflection
on the challenges and opportunities for the conduct of
real-world research in the UK.Methods
The ZQOL study was designed to provide an in-depth
evaluation of the clinical presentation and management
of HZ and PHN and the burden incurred by patients
with these conditions. Data was collected from patients
and treating physicians using a combination of validated
PRO measures and specially designed questionnaires.
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cesses are provided in Figure 1.Clinician recruitment
The management of HZ and PHN is largely based in
primary care, with referrals to secondary/tertiary care
usually reserved only for those patients with HZO or
persistent or severe PHN (ophthalmologists and specialist
pain clinics, respectively) [25]. As such, patients were to be
recruited to the ZQOL study largely by primary care cen-
tres, with a smaller proportion of patients (predominately
PHN) recruited by secondary/tertiary care specialist pain
clinics and ophthalmologists.Figure 1 Overview of ZQOL study methodology.Patient recruitment
Patients presenting to doctors with a visible HZ rash (i.e.
unilateral crop of blisters and scabs in a dermatomal
distribution) were eligible for participation. Diagnosis
of HZ was not confirmed by polymerase chain reaction
(PCR) and this could be a considered a potential limitation
of the study. However, the distinctive appearance and
distribution of the HZ rash (a unilateral crop of blisters
and scabs in a dermatomal distribution) mean that diagno-
sis of HZ is usually clear [26]. In addition PCR assessments
are fraught with logistical difficulties in primary care and
so are rarely used in practice; [27] therefore, the current
method of diagnosis is reflective of that used in ‘real world’
practice. Additional inclusion criteria of note was the focus
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data suggesting that the incidence and severity of HZ
increases significantly in this age range [4].
To promote the ecological validity of the study, extensive
exclusion criteria (as would typically be adopted in a clinical
trial) were not employed. However, to protect the integrity
of study findings, HZ patients with health impairments that
may make it difficult for them to complete the required
battery of PRO instruments (e.g. those deficits in cognitive
functioning or visual impairments) or those whose medical
background may make it difficult to interpret study results
(e.g. patients who have taken part in a clinical trial related
to HZ, pain and/or immunomodulating therapy in the
past 6 months or patients who were previously experien-
cing neuropathic pain in the dermatomal region of their
HZ rash prior to the onset of HZ) were excluded from
participation.
Data collection
At the initial site visit, once informed consent had been
obtained and participant eligibility for participation con-
firmed, patients were asked by study staff to complete a
combination of validated PRO questionnaires (including
the Zoster Brief Pain Inventory (ZBPI) [28], MOS 36-item
Short-Form Health Survey (SF-36) [29], EuroQoL 5 Di-
mensions questionnaire (EQ-5D) [30] and the Treatment
Satisfaction Questionnaire for Medication (TSQM) Version
II [31] and those specifically designed for the purposes
of the study (i.e. patient socio-demographic and clinical
history questionnaire) All questionnaires were bound in a
study booklet so to ensure standardisation of presentation
and order of completion among all patients.
There is no consensus in the research literature as to
the stage of the acute HZ episode at which pain and
HRQoL impact are at their highest [7,32]. Therefore, to
ensure that the patient-reported impact of acute HZ was
not underestimated by data collection on initial presenta-
tion, all HZ patients were provided with additional copies
of the validated PRO questionnaires which they were
asked to complete at home and return 7–14 days after
their original visit.
Clinical data and details of treatment history were
collected by the recruiting doctor from patient consultation
and medical records, and recorded using a study-specific
case report form (CRF). The CRF ensured that HZ
complications other than PHN and HZO (e.g. Delayed
contralateral hemiparesis, Ramsay Hunt syndrome and
zoster sine herpete) could be recorded; however evidence
shows that these are very rare [33].
Planned analyses
Data from the ZQOL study is to be analysed in accordance
with a formal Statistical Analysis Plan (SAP) developed a
priori. All study data is subject to extensive quality controlchecks and queries for doctor-reported information is to
be resolved where possible. Specific analyses are designed
to quantify the burden associated with HZ and PHN by
comparing mean scores on generic quality of life question-
naires (e.g. SF-36 and EQ-5D) derived from ZQOL study
participants with published aged-matched norms derived
from the general population [34,35]. In addition, analyses
design to test hypothesised differences in outcomes by
variables including age, gender, antiviral use and pain
severity are planned, Similarly, analyses designed to explore
potential predictors of pain and HRQOL are also planned.
Findings
A number of key challenges were encountered during the
conduct of the ZQOL study, which presented some
hurdles to the collection of data from a sufficient number
of patients within the pre-determined time-frame. Some
of the challenges encountered were a consequence
of organisational factors within the NHS including:
1) identification of centres willing/able to participate in the
study; 2) enrolling centres into the study (incl. obtaining
overall NRES approval for the study and R&D approval
for individual centres); and 3) recruitment of study
participants and data collection. Further details of these
challenges and strategies for overcoming or minimising
the impact of these are discussed (a summary is provided
in Table 1).
Identification of centres willing/able to participate
in the study
Difficulties in the initial recruitment and retention of
primary care centres for voluntary participation in research
studies are widely reported [36]. Furthermore, similar
hurdles have also been noted in prior UK investigations
of the burden of HZ and PHN. Scott et al. (2006) [9], for
example, approached 45 primary care centres for partici-
pation in a cross-sectional study, only 18 of which agreed
to do so [9]. This is despite the fact that all invited centres
had either participated in a previous shingles research
study [20], were associated with the Academic Department
of General Practice or had attended an educational meeting
about HZ. It is reasonable to question, therefore, whether
receptivity and actual rates of participation in such a study
would be lower among a wider sample of community
primary care centres with arguably less motivation or
vested interest for participation.
Experiences during the recruitment of centres for the
ZQOL study were indeed reflective of the above assertion,
as inherent difficulties in identifying centres with an inter-
est in participating in this study and research in general
were noted. This was particularly evident during the initial
stages of the project at which point a large number of
potential centres for participation were identified through
the use of specialist databases (e.g. www.specialistinfo.com).
Table 1 Overview of ZQOL study challenges, solutions and implications
Key challenges Solutions Future implications
1) Identification of centres willing/able to participate in the study
• Identifying centres with interest/capacity to participate in research
and the correct people to discuss participation with proved difficult
via conventional means (unsolicited mail/email).
• Limitations in dedicating time or resources to external research
projects due to clinical workloads and lack of designated support
staff were common reasons for non-participation cited by centres.
Levels of remuneration provided to centres for participation in the
study were considered insufficient by some centres.
• Availability of NHS staff participating in research having completed
Good Clinical Practice (GCP) training.
• The ZQOL study was accepted into the National
Institute for Health Research Clinical Research Network
(NIHR CRN) portfolio. NIHR were able to offer wide
range of support services including:
o Access to existing networks of centres with interests
in participating in research.
o Provision of support to centres interesting in
participating in research.
o Exploring centre eligibility for additional remuneration
for participation in NIHR CRN-approved studies.
o Delivering GCP training to centres interesting in
participating in studies.
• Experiences indicate the need for greater links between
commissioners of research and primary/secondary care centres.
• A refocusing of targets for primary care centres, to provide staff
with opportunities and incentives for partaking in research is
needed.
• Current R&D approval process makes no concessions for
non-interventional research. R&D requirements should be
proportionate to the risks associated with patient participation
in such studies.
2) Obtaining Ethics and Research & Development (R&D) Management Approval
• Information and documentation required to support R&D
applications was a barrier to participation for a number
of centres.
• Significant variation in timelines for R&D approval at a local
and regional level (i.e. England, Scotland, Wales & Northern
Ireland) led to significant delays in the study.
• R&D approval process requires that extensive tri-partite
agreements between the study sponsor, co-ordinating CRO
and R&D department be agreed and signed. However, there
is no standard template available for such agreements.
• ZQOL study organisers implemented a number of
practical solutions including:
o Minimising the number of R&D approvals by seeking
participation of clusters of centres in the same NHS trust.
o Implemented a staged study roll-out such that R&D
applications for key centres were prioritised and R&D
applications could occur in parallel to patient recruitment.
• NIHR CRN can also provide assistance:
o As a NIHR-CRN portfolio adopted study, more likely to
be considered for priority review by R&D depts.
o NIHR CRN local research network teams are able to
offer support and guidance to co-ordinating CROs
throughout England.
• Current R&D approval process makes no concessions for
non-interventional research. R&D requirements should be
proportionate to the risks associated with patient participation
in such studies.
• A move to standardise R&D approval process across NHS trusts
in England would reduce burden (and barriers) to research for
study organisers and NHS staff interested in participating in
research.
3) Recruitment of Study Participants
• Recruitment of HZ patients in primary care was slower than
envisaged, a likely result of practical and organisational factors:
o As an acute condition, HZ patients had to be recruited on
initial presentation to physicians and did not allow searches
of eligible participants via patient medical records.
o At the time of the study there will only limited opportunities
for notifications and reminders to be incorporated into
electronic-record systems on presentation of incident cases.
• Lack of unique identifiers or codes in electronic-record systems
made it difficult to identify PHN patients for participation
in the ZQOL study.
• To ensure that study recruitment quotas were met,
additional centres were recruited for participation in
the study and study timelines were extended.
• NIHR CRN local research networks and the co-ordinating
CRO were in regular contact with centre staff so to ensure
to provide support where needed.
• Standardisation of medical record keeping and greater
integration of record and monitoring systems would be to
the benefit of facilitating real-world research.
• Centres having systems in place to confirm the feasibility
of recruitment numbers and having opportunity to work
alongside study organisers could facilitate the development
of study inclusion/exclusion criteria that are less restrictive to
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conventional means (e.g. telephone/email/fax) proved
relatively unsuccessful in identifying centres willing to
participate, with only a small number of centres recruited
as a result of such efforts.
These experiences highlight the challenges for researchers
in identifying primary and secondary/tertiary care centres
willing to assist in the conduct of research. In a drive
to promote the conduct of research in the UK, in 2006
the UK Department of Health (DH) set up The National
Institute for Health Research (NIHR). A key component
of this organisation is the NIHR Clinical Research Network
(NIHR CRN), designed to provide an infrastructure by
which to facilitate the conduct of high-quality studies
within the NHS. One of the key objectives of the NIHR
CRN is ‘being able to direct researchers towards local pa-
tient populations and research capacity, so that participant
targets can be achieved’. At the heart of NIHR CRN’s
activities is the NIHR CRN Portfolio which consists of
high quality research projects that are eligible for support
and can benefit from the infra-structure of the CRN. Whist
comprising mainly randomised control trials (RCTs),
the portfolio also supports other types of well-designed
research. Once the ZQOL study had been accepted into
the NIHR CRN portfolio, the NIHR CRN played an in-
strumental role in the identification of centres that would
be willing to participate in the study. The avenue through
which potential participating centres are approached and
invited to participate in the research studies has been
identified as a successful recruitment of centres for
participation in such studies [37]. Using the support of
NIHR CRN staff in this capacity ensured that the correct
personnel (or ‘gatekeepers’) at potential participating
centres were contacted in relation to this study. There
can often be a degree of scepticism and wariness among
NHS centres as to the role of the pharmaceuticals industry
in sponsoring real-word research. That the ZQOL study
was an approved CRN portfolio study added an additional
degree of scientific credibility to the study, and was cited
by many centres as one of the reasons that they agreed to
participate in the study. Indeed, our experiences suggest
that many centres, particularly in primary care, are only
interested in participating in CRN portfolio adopted
studies.
However, even with the assistance of NIHR CRN, experi-
ences during the centre recruitment process highlighted
some barriers to centre willingness and eligibility for
participation in the study. One of the most frequently
cited barriers to participation, even among centres
showing initial interest in participating in the study,
was a lack of capacity to dedicate time or resources to
external research projects due to their already considerable
work commitments. This was particularly evident among
primary care centres; many of whom did not havedesignated support staff that were able to assist with
research activities, an assertion consistent with previous
research which has identified time and work commitments
as a major barrier to participation in primary care research
[38]. Primary care workloads are also very much influenced
by seasonal variations in illness. At the point at which
centres were being contacted regarding participation in
the ZQOL study, for example, the swine flu pandemic
had hit the UK and primary care centres were at the
forefront of vaccination delivery programmes among
patients most at risk of flu. It is likely therefore that
these extra demands on primary care centres may have
influenced decisions to decline participation in the current
study. Finally, as a further reflection of time being a pre-
mium resource within primary and secondary/tertiary care
centres, a number of centres asserted that the financial
remuneration (paid on the basis of per-patient enrolled as
is typical for these types of studies) offered for participation
in the study was not enough to justify the time that would
need to be spent on the project. Rates of remuneration for
participating centres, however, were in accordance with
UK ethics and industry-specific guidelines for payments to
healthcare professionals.
As noted, the assistance of the NIHR CRN proved
invaluable in identifying centres with a strong interest
in such research. In addition, the NIHR CRN provides
support to centres looking to participate in research to
reduce the anticipated burden that may be incurred by
site staff for taking part in such a study. There is also an
appreciation within the NIHR CRN of the remuneration
limits that may be stipulated by ethics committees for
participation in industry-led research. Sites participating
in NIHR CRN approved studies, therefore, are eligible
for additional remuneration, provided by the research
network to facilitate and promote participation in such
studies.
Current guidelines among NHS trusts require that all
researchers and centre personnel involved in clinical
research with human subjects demonstrate evidence that
they have undertaken Good Clinical Practice (GCP) train-
ing. Compliance with GCP ensures that the rights, safety
and well-being of research subjects are protected in accord-
ance with the principles of the Declaration of Helsinki and
other internationally recognised ethical guidelines. Despite
the non-interventional nature of the ZQOL study, R&D
departments were insistent that evidence of up-to-date
GCP training be provided before approving centres for
participation in the study. However, as noted many of
the centres contacted for potential participation in the
ZQOL study had only limited research experience and
a vast proportion had not completed GCP training. It was
therefore necessary for centre-staff to complete accredited-
GCP training courses, in order to fulfil this requirement,
before being considered for participation.
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adopted study, therefore, NIHR CRN staff were able to
deliver GCP training to staff at centres interested in
participating in the ZQOL study. As the content of the
GCP training is very much tailored towards clinical
research, it was also a requirement that all centres take
part in a ZQOL study-specific training session, led by the
co-ordinating contract research organisation (CRO), in
which key requirements for real-world studies and this
particular study were outlined. In addition, throughout the
course of the study, centres had access to a comprehensive
support system including NIHR CRN staff and those from
the co-ordinating CRO.
Obtaining ethics and research & development (R&D)
management approval
In accordance with current research governance frame-
works in the UK, any research involving National Health
Service (NHS) patients must be approved by the National
Research Ethics Service (NRES) to assure that ‘any antici-
pated risks, burdens or intrusions will be minimised for the
people taking part in the research and are justified by the
expected benefits for the participants or for science and
society’ [39]. While the ethical approval process for the
conduct of research in the UK is robust, in the past it has
been criticised as a significant barrier to the conduct of
academic and industry sponsored research [40-45]. These
challenges were particularly evident for multicentre studies,
where there was a requirement for independent consid-
eration of studies at a national and local level. The lack
of standardised systems and processes often resulted in
considerable administrative burden and delays in attaining
notice of approval.
In recent years, attempts have been made to streamline
the ethical review process for research involving NHS
participants. For example, changes in the NRES now
mean that it is no longer necessary for studies to be
considered and approved at both a national and a local
level. Furthermore the introduction of the on-line Inte-
grated Research Application System (IRAS) has also sought
to minimise the administrative burden associated with
NRES submissions such that all information required for
study review can be submitted via standardised and centra-
lised means. In standardising these procedures researchers
are informed that they can now expect an opinion on their
study to be received within 60 days of receipt of application
by the main REC. Indeed, NRES approval for the ZQOL
study was obtained within this timeframe.
However, in addition to obtaining NRES approval, it is
also a requirement under the 2005 Research Governance
Framework for Health and Social Care, that any research
that uses NHS patients, staff, premises or resources also
obtain formal approval from the Research & Development
(R&D) departments of each of the local NHS organisationsin which research is to take place, before research can
commence at the respective centres. Without this approval
indemnity/insurance cannot be assumed to cover the
proposed research activity.
Coordinating R&D management approval for the ZQOL
study proved to be a challenging and time consuming
process for the co-ordinating CRO and participating
centres. There are currently no concessions in place within
the R&D approval process for non-interventional research
such that the requirements and requested level of support-
ing documentation are equivalent to that expected for
a clinical trial intervention research project. Following
completion of the main NHS R&D form by the chief
investigator, therefore, there was wealth of information and
evidence to be provided by the principal investigator at
each of the participating centres to fulfil R&D require-
ments. This included completion of a Site-Specific
Information Form (SSI) to be submitted electronically
via the IRAS system alongside evidence of GCP training
and up-to-date Curriculum Vitaes (CVs) for all staff
involved in the project. As a result of the demands of the
R&D approval process, a number of centres who had
originally agreed to participate in the study withdrew
from participation.
Despite recent attempts to standardise the NRES and
R&D application process via introduction of the IRAS
system, experiences during the ZQOL study highlight a
distinct lack of standardisation in R&D approval require-
ments and processes. Firstly, unlike NRES applications
for which there is a designated 60-day review policy, there
are no fixed timelines for R&D. Applications for R&D
approval can be made in parallel with NRES submissions
but experiences from the ZQOL study highlighted wide
variation at a local and regional level (i.e. England,
Scotland, Wales and Northern Ireland), with approval
being obtaining in as little as 3–4 days or as much as
152 days from submission of R&D application. The
average time from R&D submission to approval across
sites enrolled in the study was 45 days. As part of the
R&D approval process it was also necessary for extensive
tri-partite agreements to be agreed and signed by the study
sponsor, co-ordinating CRO and R&D department. There
currently exists no standardised template specifically
designed for non-interventional research, such that the
time taken to negotiate these agreements contributed
to overall approval timelines.
The difficulties faced by study organisers in terms of
obtaining R&D approval is recognised by the NIHR
CRN whose local research network teams are able to
offer support and guidance to co-ordinating CROs and
participating centres throughout England. Furthermore, as
an NIHR-CRN portfolio-adopted study the ZQOL study
is also likely to have been considered for priority review by
R&D departments. Indeed, studies now adopted into the
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co-ordinated system for gaining NHS permission. In
addition to the support provided by NIHR CRN, there
are a number of practical solutions that can be adopted
to minimise the burden of R&D submissions for multi-
centre studies. Firstly, while it was important to ensure
adequate geographical distribution of centres throughout
the UK, it was possible to minimise the administrative
burden of R&D submissions by seeking participation of
clusters of primary care centres within the same NHS
trust. Secondly, a staged study roll-out meant that once
approved by NRES, R&D approvals for pending study
centres could be on-going whilst the study was in field.
Recruitment of study participants
Sample size calculations are important in observational
research to ensure that studies possesses adequate statistical
power to allow accurate, reliable and valid conclusions
to be drawn from study data [46]. However, failure to reach
designated recruitment targets is a commonly reported
problem in primary care research with less than 33% of
studies meeting their recruitment target and approximately
45% recruiting less than 80% of their original target [47].
Consistent with this assertion, difficulties recruiting HZ
patients in the UK have been reported previously. Scott
et al. (2006) [9], for example, estimated that a population
of 150,000 served by their study centres would identify
200–300 cases of HZ and 45 cases of PHN in 8 months
[9]. In reality, however, only 96 patients were referred to
the study, of which 70 enrolled and only 65 completed,
highlighting the fact that once centres are enrolled, chal-
lenges still exist in terms of recruiting study participants.
This raises the question as to whether there is a realistic
understanding and appreciation of the practical challenge
pertaining to recruitment. If centres could utilise a system
of validation to confirm the feasibility of recruitment num-
bers and work with study organisers to develop inclusion/
exclusion criteria that foster a more dynamic approach to
research, improvements could be realised.
Prior to study start-up a small scale feasibility study was
conducted, the findings of which estimated lead times for
patient recruitment to be 6–8 months, with each centre
expected to recruit approximately 7 HZ and 5 PHN
patients over this period. Contrary to expectations,
interim recruitment rates for the ZQOL study revealed
slower recruitment rates than originally envisaged, par-
ticularly among primary care centres. Furthermore, des-
pite going through the hurdle of the R&D process, 8
participating centres did not contribute any data to the
study. There are a number of factors thought to have
contributed to the slow recruitment rate within such
centres. Firstly, this may be explained by constraints in
terms of resources for obtaining patient and physician
completed information. Secondly, in accordance withthe typical management of HZ and PHN, specified recruit-
ment targets assumed that the majority of HZ patients
would be recruited from primary care. As an acute disease,
primary care centres were to recruit patients with incident
cases of HZ on initial presentation to staff at participating
centres. As such, there was no opportunity to utilise centre
records or databases to identify existing cohorts of patients
who could be invited to participate in the study. Fur-
thermore, at the time of the study there was only limited
opportunity for study notifications and reminders to be
incorporated within electronic-record systems used by
centres (e.g. EMIS, iSOFT) on presentation of incident
cases. In addition, it became apparent, during the course
of the study, that there was little standardisation in
record-keeping practices in terms of systems used (e.g.
EMIS, iSOFT) and information recorded by centres. In
many cases, for example, there was no unique identifier or
code in place to identify patients who may be experiencing
PHN, offering support to prior assertions that as many as
80 % of patients with PHN may not have this diagnosis
specified within administrative systems [16]. Acknowledging
this coding issue, it is important to consider alternative
strategies to identify eligible participants.
Finally, it is worth noting that remuneration for patients
was not identified as a significant barrier to recruitment
to the ZQOL study. Patient incentives were designed to
cover estimated out-of-pocket expenses for participation
in the study only (e.g. travel to and from the study site).
This ensured that, in accordance with ethical standards,
informed consent to participate in the study was free from
coercion and undue influence that may occur when
incentives offered to research participants are in excess
of the level of compensation expected.
As is a common consequence in such studies [36], due
to the experience of such difficulties and to ensure that
recruitment targets were met, study timelines were
extended. To account for centres where recruitment was
proving particularly difficult, additional centres were also
enrolled to the study, where possible within the same
NHS trust so to minimise the burden of the R&D approval
process. The help of the NIHR CRN local research teams
was also important for liaising with staff at participating
centres as well as the co-ordinating CRO to address any
difficulties encountered and provide assistance where
needed. In addition to maintain motivation and investment
in the study among participating centres, centre staff were
routinely informed of the status of the project via regular
project update calls. In addition, more formal written
updates (e.g. end of year update memos, newsletters,
etc.) were sent to all participating centres.
In light of these initiatives, pre-specified recruitment
targets for the ZQOL study were eventually met. The final
list of participating study sites represented a diverse spread
of primary and secondary care centres throughout the UK,
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Discussion
Recent years have seen a decline in the conduct of clinical
trial research in the UK [48]. However, a key feature of the
UK Government’s reforms to the NHS is the promotion
of the conduct of research “to improve health outcomes
and reduce inequalities” [21]. One way to ensure contin-
ued growth in the UK research arena, as recognised by the
Association of the British Pharmaceutical Industry (ABPI),
is to promote the conduct of ‘real-world’ research in a UK
context [49]. Whilst randomised control trials (RCTs)
are able to provide evidence of the efficacy and safety
of medical interventions, real-world studies provide
important generalisable evidence of the ‘effectiveness’
and value of such interventions in normal clinical practice.
The value of such evidence is being increasingly recognised
by regulatory authorities; in particular the generation of
robust real-world evidence will be key to the Value-Based
Pricing scheme applied to medicines, which is set to be
introduced to the NHS from 2014 [50]. Real-world data
concerning current burden of disease and unmet medical
need will be important for informing economic and budget
impact models used to determine cost-effectiveness thresh-
olds for pricing and reimbursement.
As the largest and first UK-wide investigation conducted
within HZ and PHN patients, the ZQOL study was de-
signed to provide much needed UK-specific information
on the impact of HZ and PHN and their management,
from both a human and wider economic perspective.
However, as highlighted challenges and hurdles were
encountered during the course of this study, which could
have prevented achievement of participant recruitment
targets (essential to ensure the statistical power of the
study) within the pre-determined time frame. Some of the
contributory factors are arguably reflective of organisa-
tional, structural and cultural characteristics of the NHS
and its associated organisations.
In recognition of some of these challenges, support
networks and modification to NHS systems have been
put into place. As noted, for example, local research
networks provided by the NIHR CRN are able to guide
and support research co-ordinators right throughout the
research process. The introduction of the IRAS system has
also sought to streamline and reduce the administrative
burden of the NRES and R&D approval process. However,
whilst recognising the need to assure scientific quality
and ethical standards in real-world studies, current
systems and requirements are considerable hindrance
to the conduct of such studies. At present, for example,
current regulatory and governance frameworks do not
distinguish ‘non-interventional’ real-world studies from
‘interventional’ RCTs. As such, many of the requirementsimposed on real-world studies (e.g. need for all participat-
ing NHS staff to have GCP training), seem disproportionate
to the risks associated with such studies. Streamlining and
standardising this process, therefore, would go a great way
to minimising the barriers to the conduct of such studies.
As highlighted during the conduct of the current study,
it is important to note that should the UK Government
wish to promote health research in the UK, then such
research needs to become engrained within the culture of
the NHS. For primary care centres, in particular, a lack of
capacity for research in the context of current workloads
and limited research experience was evident. A refocusing
of targets for primary care centres to provide staff with
opportunities and incentives for partaking in research is
therefore needed.
Whilst the current paper has focussed specifically on
challenges to the conduct of real-world studies in the
UK, it is important to appreciate that similar difficulties
also face researchers in other countries throughout
Europe. However, increasing recognition and appreciation
of these difficulties by UK authorities (such as the ABPI)
is designed to promote the adaptation of current systems
and process in order to facilitate the conduct of such stud-
ies. This is especially important as the need for information
derived from real-world studies grows ever greater. In
considering the implementation of these changes, the
UK can be positioned at the forefront of health research.
Conclusions
The value of ‘real-world’ research is being increasingly
recognised by healthcare decision makers. The ZQOL
study demonstrates that opportunities exist for real-word
research in the UK, but also highlights significant chal-
lenges that may present for researchers wishing to conduct
such research in the UK. These experiences suggest that
initiatives designed to promote and enable the involvement
of healthcare professionals in research, streamline the R&D
approval process and assist with the identification of eligible
participants would help to further facilitate the generation
of real-world evidence in the UK to inform healthcare
decisions for UK patients.
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